RNA interference technologies and therapeutics: from basic research to products.
RNA interference (RNAi) is a natural cellular process that regulates gene expression by a highly precise mechanism of sequence-directed gene silencing at the stage of translation by degrading specific messenger RNAs or blocking translation. In recent years, the use of RNAi for therapeutic applications has gained considerable momentum. It has been suggested that most of the novel disease-associated targets that have been identified are not 'druggable' with conventional approaches. However, any disease-causing gene and any cell type or tissue can potentially be targeted with RNAi. This review focuses on the current knowledge of RNAi mechanisms and the safety issues associated with its potential use in a therapeutic setting. Some of the most important aspects to consider when working towards the application of RNAi-based products in a clinical setting have been related to achieving high efficacies and enhanced stability profiles through a careful design of the nucleic acid sequence and the introduction of chemical modifications, but most of all, to developing improved delivery systems, both viral and non-viral. These new delivery systems allow for these products to reach the desired target cells, tissues or organs in a highly specific manner and after administration of the lowest possible doses. Various routes of application and target locations are currently being addressed in order to develop effective delivery systems for different targets and pathologies, including infectious pathologies, genetic pathologies and diseases associated with dysregulation of endogenous microRNAs. As with any new technology, several challenges and important aspects to be considered have risen on the road to clinical intervention, e.g. correct design of preclinical toxicology studies, regulatory concerns, and intellectual property protection. The main advantages related to the use of RNAi-based products in a clinical setting, and the latest clinical and preclinical studies using these compounds, are reviewed.
López-Fraga
Marta
M
Sylentis SAU, Parque Tecnológico de Madrid, Madrid, Spain. mlfraga33@gmail.com
Martínez
Tamara
T
Jiménez
Ana
A
D000818:Animals; D001424:Bacterial Infections / Q000628:therapy; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D007113:Immunity, Innate; D008055:Lipids / Q000008:administration & dosage; D035683:MicroRNAs / Q000037:antagonists & inhibitors; D009154:Mutation; D010272:Parasitic Diseases / Q000628:therapy; D010455:Peptides / Q000008:administration & dosage; D011108:Polymers / Q000008:administration & dosage; D020641:Polymorphism, Single Nucleotide; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000235:genetics; D014777:Virus Diseases / Q000628:therapy
D008055:Lipids; D035683:MicroRNAs; D010455:Peptides; D011108:Polymers; D034741:RNA, Small Interfering